Great Basin Scientific Inc. (fka GBSNQ)

[guidelines]

i stand by the current value points:

- bargain basement PPS for a biotech with sales revenues
- sexy product space (Infection/Dx)
- just finished an R/S, with a reasonable share structure (A/S O/S)
- company has to give this last R/S a few months to resolve the PPS
- meanwhile there will be 2 FDA approvals for new assays
- an interim Q1 sales report PR, and as aggressive as the management is to increase PPS - probably a couple of decent PRs in between.

Prognosis: patient has decent insurance, with an increasing life expectancy with double digit silver vital signs.